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Abstract
More	than	1	million	people	dies	worldwide	due	to	 lung	cancer	which	is	the	first	most	incident	cancer	 in	males	and	the	third	
in	females.	Only	early	diagnosis	makes	possible	to	achieve	long-lasting	remission	or	even	cure	the	disease.	Unfortunately,	no	
tumour	marker	to	achieve	this	goal	has	been	identified,	yet.	One	of	putative	lung	cancer	markers	is	free	circulating	tumor	DNA.	
Its	concentration	seems	to	be	related	to	cancer	burden.	Moreover,	it	can	be	subjected	to	mutational	status	analysis	allowing	for	
introduction	of	targeted	treatment.	This	led	to	the	idea	of	liquid	biopsy	which	can	substitute	for	a standard	biopsy	not	feasible	
in	certain	clinical	circumstances.	Assessment	of	cell	free	tumour	DNA	can	also	inform	about	progression/recurrence	of	cancer	
and	may	have	a prognostic	value.	Therefore,	the	aim	of	this	article	is	to	review	on	free	circulating	DNA	as	a potential	marker	in	
lung	cancer.	
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Biomarkers of malignancy 
Incidence of malignant tumours worldwide is 
growing, making them a serious epidemiological 
hazard. The data obtained from the National Can-
cer Registry over the last three decades confirm 
that the incidence of malignant tumours in Poland 
has increased twice (from 64 700 in 1980 to above 
140 500 cases in 2010); in 2013, this number re-
ached almost 156 500 cases. Lung cancer occupies 
the first place in males (18.7%) and the third place 
in females (8.8%) as the most frequently diagnosed 
malignancy [1]. Early detection allows to imple-
ment an optimal treatment on time, and consequ-
ently to obtain a long overall or progression-free 
survival. To this end, screening diagnostic tests 
have been pursued, and recently a low-dose CT scan 
has been proposed as a screening tool for lung can-
cer in a population at risk, i.e. heavy smokers [2, 3].
Apart from imaging studies, a different appro-
ach to screening have been based on biomarkers 
of cancer, which ideally, should be a sensitive 
(but also relatively specific) substance present in 
body fluids, e.g. blood, urine or sputum, definitely 
easier to collect than cancer tissue [4]. Moreover, 
despite diagnostic potential, biomarkers can also 
exhibit predictive (of a response to treatment) or 
prognostic (overall survival or progression-free 
survival) attributes [5].
From the historic perspective, the first cancer 
biomarker was an immunoglobulin present in the 
urine of patients with multiple myeloma, which 
was identified as early as in 1848 [6]. The twen-
tieth century witnessed discoveries of numerous 
hormones, proteins and enzymes, marking pa-
tients with a particular malignancy. In the 1960s, 
an alpha-fetoprotein and CEA (carcinoembryonic 
antigen) were identified in blood. Subsequently, 
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other proteins, such as CA 15.2 (cancer antigen), 
CA 19.9, CA 125 and PSA (prostate specific an-
tigen) were discovered and validated. All these 
substances have been widely used in monitoring 
therapy, evaluation of radical surgical treatment 
and in some cases, allowed for early detection of 
cancer. However, their major drawbacks, limiting 
clinical merit, have been insufficient sensitivity or 
specificity, and consequently not sufficiently high 
predictive values. Moreover, as a potential tool to 
monitor cancer progression, their concentration 
in body fluids weakly correlated with a clinical 
stage of the tumour [5]. Technological progress 
which took place at the end of the twentieth cen-
tury contributed to the development of molecular 
diagnostics. In effect, circulating cell-free tumour 
DNA (ct-DNA) was identified in blood and propo-
sed as a plausible biomarker of malignancy [7, 8].
Cell-free circulating DNA
Circulating blood contains natural cell-free 
DNA (cf-DNA) that comes mostly from apoptotic 
cells. Rapid turnover of tumour cells during gro-
wth, metastatic disease or cancer therapy, results 
in a release of a number of molecular biomarkers 
into the peripheral blood. One of these is ct-DNA 
that differs from its physiological counterpart by 
more variable helix length and by the presence 
of specific mutations. Apoptotic cf-DNA length is 
a multiple of 180–200 base pairs from nucleosome 
derived fragments while ct-DNA reveals variable 
and usually shorter or longer strand length with 
fragments over 10kb considered characteristic of 
necrosis [9, 10]. Obviously, in subjects with no 
malignancy, only physiological cf-DNA is found 
in blood. In case of cancer, concentration of its 
neoplastic counterpart is highly variable and 
may constitute from less than 1 up to 90% of to-
tal cf-DNA, which probably depends on tumour 
type and stage [11, 12]. For instance, ct-DNA was 
present in almost all patients with colorectal or 
pancreatic carcinoma, while in minority of cases 
with prostate or renal cell carcinoma [13]. The-
oretically, to detect circulating ct-DNA in blood, 
the cancer must consist of at least 50 million cells, 
which is a  small number, considering the fact 
that a tumour 7–10 mm in diameter that can be 
detected by imaging studies consists of at least 1 
billion cells [5]. In effect, detecting ct-DNA may 
be more sensitive than other diagnostic modalities 
and may plausibly allow for early diagnosis.
Moreover, ct-DNA may be subjected to quali-
tative analysis of a mutational status of a tumour 
[12, 14]. Some of the mutations detectable in ct
-DNA are believed to be responsible for malignant 
transformation, leading to uncontrollable growth 
and cell divisions, hence, they are called driver 
or primary mutations and, of note, they can be 
a target of specific drugs, e.g. inhibitors of recep-
tor kinases. Other mutations are new mutations 
occurring in the course of cancer (secondary ones) 
which may be responsible for the emergence of 
resistance to cancer therapy [15].
Cell-free circulating DNA as a source of material 
to assess mutational status of the tumour
The assessment of mutational status of the 
tumour is paramount for introduction of specific 
treatment, e.g. inhibitors of receptor kinases. 
Still, an analysis of material from biopsy of 
a  tumour or metastases is considered the gold 
standard. Nevertheless, this standard has been 
lately challenged by some discoveries implying 
heterogeneity of mutational status within tumour 
or between tumour and metastases. For instance, 
we have recently found that the material from 
separate parts of the tumour specimen harboured 
different KRAS mutation at codon 12, or some 
parts of the tumour harboured a wild gene while 
the others a mutated one [16]. Therefore, finding 
no mutation on a standard biopsy may not always 
be a  true negative result, meaning the lack of 
sensitivity, and in effect low negative predictive 
value. So, the analysis of ct-DNA may plausibly 
be a better source of material as it presumably 
derives from all parts of the tumour, with cells 
harbouring different mutations or a wild gene 
simultaneously. Therefore, an isolation of ct-D-
NA from a small amount of blood for analysis of 
mutations was called a “liquid biopsy” [12].
What is more important, in some patients, it 
is not feasible to obtain a suitable tissue sample 
for assessment of mutations relevant to intro-
duction of a second line treatment. This may be 
due to insufficient amount of the biopsy material 
or safety, ethical or technical issues entailed to 
re-biopsy. Detection of ct-DNA in the peripheral 
blood might be an alternative procedure. A small 
sample of blood contains enough cf-DNA (inclu-
ding ct-DNA), to be used for rapid genotyping in 
order to detect mutations. An analysis of ct-DNA 
could be repeated any time as needed and should 
cause neglectable discomfort to patients [5, 17]. 
Moreover, as a half time of ct-DNA is only about 
2 hours, it can reflect changing mutational status 
of a  tumour [12]. Genetic material obtained in 
this way is biologically rich enough to enable 
detections of mutations within ct-DNA and its 
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quantitative evaluation. For instance, Sacher 
et al. found that analysis of common KRAS 
and EGFR mutations in ct-DNA among NSCLC 
patients revealed high positive predictive va-
lue potentially informing an optimal treatment 
[18]. Further, recently published meta-analysis 
showed lower survival in NSCLC patients with 
KRAS mutation detected in ct-DNA [19]. Another 
approach to ct-DNA analysis was to look for 
methylation of promoters of tumour suppressor 
genes. Disappointingly, methylation analysis of 
various promotors of genes implicated in NSCLC 
pathogenesis (e.g. p16, APC, RARb) was plagued 
by low sensitivity [20]. 
Finally, regulatory bodies in Europe and the 
USA have recently approved some diagnostic tests 
detecting EGFR receptor mutations in ct-DNA 
to inform specific treatment in case no NSCLC 
tissue can be harvested directly from the tumour 
or metastases [21–24]. Nevertheless, the problem 
highlighted by the ASSESS study was too low 
sensitivity of only about 50% leading to many 
false negative results, thus leaving many patients 
harbouring this driver mutation without optimal 
treatment [25].
Concentration of cell-free circulating DNA 
as a predictive biomarker
The idea that the heavier tumour burden is 
reflected by the higher concentration of ct-DNA 
and by this means it can be a predictor of survival 
is quite attractive. However, the published data 
on the value of a ct-DNA as a predictor of survival 
in solid tumours are somewhat contradictory. 
In one of the first studies, Gautschi et al. found 
that elevated concentration of ct-DNA correlated 
with poor survival and tumour progression after 
chemotherapy [26]. Likewise, Sozzi et al. [27] 
reported overall high median ct-DNA in patients 
relapsing in the course of NSCLC, but clinical 
usefulness of this finding was weakened by some 
relapsing patients with low level of ct-DNA, i.e. 
false negatives. Nygaard et al. [28] conducted 
a study on a small group of 53 patients and ob-
served significantly shorter overall survival and 
progression-free survival in a  subgroup of pa-
tients with the upper highest quartile of ct-DNA 
concentration. Similar results were obtained by 
Tissot et al. [29], namely ct-DNA at the highest 
tertile of concentration spectrum was associated 
with shorter overall survival and progression- free 
survival. Extracellular DNA can also be detected 
in other easily obtainable body fluids, e.g. exhaled 
breath condensate. In NSCLC patients with con-
firmed KRAS mutation at codon 12 after a tumour 
resection, a ratio of mutated to wild type KRAS 
in exhaled breath condensate decreased over one 
month of observation [30]. This phenomenon may 
possibly be used in monitoring patients for com-
pleteness of resection or recurrence of a tumour. 
In line with this assumption are results published 
by Kumar et al. [31], namely high basal ct-DNA 
concentration, and smaller decreases of its level 
observed in the course of chemotherapy were 
related to worse outcome.
Quite the contrary, a study published by Li 
et al. [32] on a group of 103 patients showed no 
relation between concentrations of ct-DNA before 
any systemic treatment and the survival. Also ct
-DNA changes did not correlate with the RECIST 
(Response Evaluation Criteria in Solid Tumours) 
criteria of response to treatment. Similarly, ct
-DNA concentration did not predict survival in 
patients treated with tyrosine kinase inhibitors 
[33]. Nevertheless, a meta-analysis of 16 studies 
showed that a high ct-DNA concentration incre-
ased the risk of death of lung cancer patients but 
did not affect progression- free survival [34].
Concentration of cell-free circulating DNA 
as a diagnostic biomarker
Another way to assess clinical value of ct
-DNA is quantitative analysis with presumption 
that in malignancy, higher concentration can 
have discriminatory value and allow for an early, 
non-invasive cancer detection. Szpechcinski et al. 
[35] found that ct-DNA level was higher in NSCLC 
patients compared to healthy controls and sub-
jects suffering from chronic inflammatory lung 
diseases. Similarly, in another work by this group, 
ct-DNA concentration was markedly elevated in 
NSCLC vs. patients with benign lung nodules 
[36]. Nevertheless, at the discriminatory concen-
tration levels proposed by the authors calculated 
predictive values were below 90%, not allowing 
for ruling in or out NSCL diagnosis. Further, Leng 
et al. [37] showed that in NSCLC patients higher 
and differential ct-DNA concentrations were 
observed compared to tuberculosis group. Moreo-
ver, the authors emphasised a greater sensitivity 
of ct-DNA compared to traditional biomarkers, 
such as CA125, NSE and CEA. Unfortunately, 
calculating predictive values from data provided 
by the authors yields mediocre results, not fully 
supporting the overoptimistic conclusions. 
Conclusions
A small sample of blood is sufficient to deter-
mine genetic changes in the tumour by analysis 
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of ct-DNA. Determination of new mutations and 
assessment of concentration of ct-DNA seem to 
increasingly have place in non-invasive cancer 
screening. Nevertheless, the lack of standardi-
sation of the methods used to assess ct-DNA is 
a major drawback and hinders wider clinical 
application. Therefore, standardisation of rese-
arch on ct-DNA regarding its reference plasma 
concentration and in effect cut-off values for pa-
tients with NSCLC is of paramount importance. 
Moreover, clinical evaluation on larger groups 
of patients in prospective studies in respect to 
NSCLC diagnosis and prognosis may lead to wide 
implementation of liquid biopsy. Perhaps in the 
near future, this can be an robust alternative to 
a traditional tumour biopsy.
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